Overview

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alcon Research
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Travoprost
Criteria
Inclusion Criteria:

- ≥18 years;

- IOP=16-30mmHg

- OH or OAG with visual filed abnormality:

1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal
meridian, that have p <5% on the prepapillary diameter plot, one of which must
have p <1%,

2. Glaucoma Hemifield Test outside normal limits,

3. Corrected Pattern Standard Deviation with p <5%

Exclusion Criteria:

- Previous damage of anterior chamber angle;

- ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual
Acuity (logMAR) <1.0;

- contact lens wearer;

- severe central field loss;

- uncontrolled cardiovascular, hepatic or renal disease;

- any medication within past 1 month.